Evidence map›Paper›PMID 40673864›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

PLAUR

Shaoqing Liu, Yanzhao Zhou, Gaoxiang Li, Bingwen Zhu, Fang Wu, Jinxue Zhou, Xiaobing Chen, Bo Qin, Yanxia Gao, Fazhan Wang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Review
  2. Leveraging Microphysiological Systems to Facilitate Neutrophil-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. PLAURAdvanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Shaoqing LiuDepartment of Breast Surgery, Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Yanzhao ZhouDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Gaoxiang LiState Key Laboratory of Systems Medicine for Cancer, Division of Cardiology, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Bingwen ZhuInstitute of Infection and Immunity, Henan Academy of Innovations in Medical Science, Zhengzhou, 451163, China.
Fang WuDepartment of Immunology, School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
Jinxue ZhouDepartment of Hepatobiliary and Pancreatic Surgery, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Xiaobing ChenDepartment of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, 450008, China.
Bo QinDepartment of Breast Surgery, Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Yanxia GaoState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Infection and Immunity, Henan Key Laboratory of Critical Care Medicine, Department of Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Fazhan WangMedical Research Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, Henan, 450052, China.
Yong JiangState Key Laboratory of Metabolic Dysregulation & Prevention and Treatment of Esophageal Cancer, Henan International Joint Laboratory of Infection and Immunity, Henan Key Laboratory of Critical Care Medicine, Department of Emergency Medicine, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.
Wenxin XuDepartment of Breast Surgery, Translational Medical Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450001, China.ORCID https://orcid.org/0009-0006-5513-0170

Funding

Central Plains Science and Technology Innovation Young Top Talents Project and Natural Science Foundation of Henan Province 252300421432National Natural Science Foundation of China 82130063National Natural Science Foundation of China 82241061
6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC) is characterized by an immunosuppressive tumor microenvironment (TME) that limits the efficacy of immune checkpoint inhibitors. However, the role of distinct neutrophil subsets within the TME in mediating tumor resistance to immunotherapy remains poorly understood. Here, the present study reveals that the urokinase-type plasminogen activator receptor (PLAUR)

Indexed as

Carcinoma, HepatocellularDrug Resistance, NeoplasmLiver NeoplasmsNeutrophilsProgrammed Cell Death 1 ReceptorReceptors, Urokinase Plasminogen ActivatorTumor MicroenvironmentAnimalsHumansImmune Checkpoint InhibitorsImmunotherapyMiceImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorReceptors, Urokinase Plasminogen Activatorbiomarkerhepatocellular carcinomaimmunotherapyneutrophilurokinase‐type plasminogen activator receptor

Identifiers

PMID40673864
PMCPMC12520528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.